According to sources familiar with the matter, the U.S. government is unlikely to announce investigations or tariffs targeting the pharmaceutical sector for at least several weeks.
The delay indicates that any potential enforcement actions, including new probes or import tariffs, remain on hold temporarily. Industry observers continue monitoring for developments as timelines extend beyond initial expectations.